← Leaderboards
William Joseph Murphy
University Of Nevada Reno
$21,521,926
Attributed
$21,521,926
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$21,521,926 · 9
By mechanism
R01$21,521,926 · 9
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneTumorMalignant NeoplasmsBaseMediatingCytokineCellsAffectResponseProductionCancer TherapyAllogenicToxic EffectNatural Killer CellsInsightReceptorIn VivoImmunotherapyT-LymphocyteInflammatoryPlayRelapseCessation Of LifeImmune Response
Grant awards (69)
Multispecies Comparison of the Impact of Obesity on GVHD/GVT$583,530
R01 · FY2021 · CA · contact PI
Immunoregulatory and effector roles of natural killer cell subsets$463,328
R01 · FY2021 · HL · contact PI
Multispecies Comparison of the Impact of Obesity on GVHD/GVT$606,398
R01 · FY2020 · CA · contact PI
Immunoregulatory and effector roles of natural killer cell subsets$463,328
R01 · FY2020 · HL · contact PI
Multispecies Comparison of the Impact of Obesity on GVHD/GVT$752,739
R01 · FY2019 · CA · contact PI
Immunoregulatory and effector roles of natural killer cell subsets$489,954
R01 · FY2019 · HL · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$352,155
R01 · FY2019 · CA · contact PI
Multispecies Comparison of the Impact of Obesity on GVHD/GVT$626,619
R01 · FY2018 · CA · contact PI
Immunoregulatory and effector roles of natural killer cell subsets$463,328
R01 · FY2018 · HL · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$365,919
R01 · FY2018 · CA · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$101,761
R01 · FY2018 · CA · contact PI
Immunoregulatory and effector roles of natural killer cell subsets$28,440
R01 · FY2018 · HL · contact PI
Multispecies Comparison of the Impact of Obesity on GVHD/GVT$630,732
R01 · FY2017 · CA · contact PI
1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer$555,499
R01 · FY2017 · CA · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$365,919
R01 · FY2017 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$302,123
R01 · FY2017 · CA · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$70,981
R01 · FY2017 · CA · contact PI
1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer$568,802
R01 · FY2016 · CA · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$365,534
R01 · FY2016 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$322,422
R01 · FY2016 · CA · contact PI
1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer$580,868
R01 · FY2015 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$431,220
R01 · FY2015 · HL · contact PI
Radio-immunotherapy to Target Cancer Stem Cells in Solid Tumor Malignancies$364,015
R01 · FY2015 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$302,123
R01 · FY2015 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$59,621
R01 · FY2015 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$391,771
R01 · FY2014 · HL · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$293,059
R01 · FY2014 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$57,833
R01 · FY2014 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$19,259
R01 · FY2014 · HL · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$415,552
R01 · FY2013 · HL · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$302,123
R01 · FY2013 · CA · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$253,005
R01 · FY2013 · CA · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$55,904
R01 · FY2013 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$39,322
R01 · FY2013 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$376,334
R01 · FY2012 · HL · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$269,154
R01 · FY2012 · CA · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$43,191
R01 · FY2012 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$15,176
R01 · FY2012 · HL · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$268,280
R01 · FY2011 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$382,500
R01 · FY2010 · HL · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$278,832
R01 · FY2010 · CA · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$275,675
R01 · FY2010 · CA · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$289,821
R01 · FY2009 · CA · contact PI
Molecular targeting agents in GVHD/GVT: Role of cytokines and T cell subsets$275,675
R01 · FY2009 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$238,850
R01 · FY2009 · HL · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$112,400
R01 · FY2009 · HL · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$350,000
R01 · FY2008 · HL · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$287,574
R01 · FY2008 · CA · contact PI
Proteasome inhibitor (PS-341) and adoptive immunotherapy$253,662
R01 · FY2008 · CA · contact PI
Positive and Negative Regulation of Natural Killer Cells After BMT$350,000
R01 · FY2007 · HL · contact PI
Neuroendocrine Hormones to Promote Immune Reconstitution$309,344
R01 · FY2007 · AG · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$287,574
R01 · FY2007 · CA · contact PI
Proteasome inhibitor (PS-341) and adoptive immunotherapy$253,662
R01 · FY2007 · CA · contact PI
Neuroendocrine Hormones to Promote Immune Reconstitution$318,584
R01 · FY2006 · AG · contact PI
Immunotherapy by CD40 stimulation and IL-2 against Cancer$296,163
R01 · FY2006 · CA · contact PI
Proteasome inhibitor (PS-341) and adoptive immunotherapy$281,238
R01 · FY2006 · CA · contact PI
Immunotherapy using NK cells to promote engraftment$252,035
R01 · FY2006 · CA · contact PI
Neuroendocrine Hormones to Promote Immune Reconstitution$326,250
R01 · FY2005 · AG
Proteasome inhibitor (PS-341) and adoptive immunotherapy$267,525
R01 · FY2005 · CA
Immunotherapy using NK cells to promote engraftment$258,100
R01 · FY2005 · CA
Neuroendocrine Hormones to Promote Immune Reconstitution$326,250
R01 · FY2004 · AG
IT by CD40 stimulation and IL2 against renal cell carcin$290,363
R01 · FY2004 · CA
Proteasome inhibitor (PS-341) and adoptive immunotherapy$261,252
R01 · FY2004 · CA
Immunotherapy using NK cells to promote engraftment$258,100
R01 · FY2004 · CA
Neuroendocrine Hormones to Promote Immune Reconstitution$326,250
R01 · FY2003 · AG
IT by CD40 stimulation and IL2 against renal cell carcin$290,363
R01 · FY2003 · CA
Immunotherapy using NK cells to promote engraftment$258,100
R01 · FY2003 · CA
IT by CD40 stimulation and IL2 against renal cell carcin$290,363
R01 · FY2002 · CA
Immunotherapy using NK cells to promote engraftment$258,100
R01 · FY2002 · CA